Lv1
40 积分 2024-08-02 加入
The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) in advanced non-small cell lung cancer: A multicenter retrospective observational study in China
2天前
已关闭
Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy
3个月前
已完结
皖公网安备34019202002308
